资讯 | 康龙化成宣布取得希麦迪控股权

2019-05-21

康龙化成宣布取得希麦迪控股权

旨在增强中国临床开发服务能力

 

北京,2019年5月21日—康龙化成宣布完成对南京思睿生物科技有限公司(下称“思睿生物”)及其全资子公司南京希麦迪医药科技有限公司(下称“希麦迪”)的新一轮投资,通过此次交易,康龙化成获得思睿生物及希麦迪的控股权。这是继2018年战略投资希麦迪之后的跟进投资,是对希麦迪业务能力的进一步认可,同时表明了康龙化成对发展临床开发服务能力的坚定决心。获取希麦迪的控股权是康龙化成全球临床开发服务平台建设的战略部署之一,旨在进一步提升临床开发服务能力,强化中国希麦迪与美国临床药理中心(CPC)间的协同效应,提高综合服务水平,为客户创造价值。

康龙化成董事长兼CEO楼柏良博士表示:“欢迎希麦迪加入康龙化成大家庭。通过此次交易,康龙化成的临床服务能力在本土得到延伸。作为康龙化成全球临床开发能力建设的战略部署之一,通过中、英、美三地的密切合作,我们独具特色的一体化临床开发服务平台的协同效应将会愈加明显,必将为国内外合作伙伴提供更高水平的服务,加快临床开发进程,为合作伙伴、员工和股东创造价值。”

希麦迪首席执行官吴昱博士表示:“很高兴成为康龙化成大家庭的一员!希麦迪一直致力于为合作伙伴提供高质量的临床服务。我们相信这种国际化的全方位研发平台整合必将为客户提供更高水平的服务,为医药研发特别是临床开发做出贡献。”

通过对临床开发不同业务能力的整合,进一步夯实了康龙化成全方位药物发现、开发服务平台,再次证明了康龙化成致力于成为全球新药研发服务行业领军企业的决心,并将始终坚持使命:以最高水平的研发服务,帮助伙伴们成功开发新药,为人类健康贡献康龙化成智慧!

关于康龙化成

康龙化成新药技术股份有限公司,成立于2004年,是国际领先的生命科学研发服务企业。经过十多年的快速发展,康龙化成打造了全方位的药物研发一体化平台,贯穿合成与合成及药物化学、生物、药物代谢及药代动力学、药理、药物安全评价、放射标记化学、放射标记代谢、临床药理、临床分析、原料药和成品药的工艺优化及生产等领域。康龙化成在中国、美国、英国均有运营实体,拥有6,500多名员工,一流的人才队伍,高质量的研发服务,获得了业界的广泛认可,与北美、欧洲、日本和中国的各医药公司/机构保持着长期、稳固的合作关系。

详情请访问公司网站:www.pharmaron.com

关于希麦迪

思睿生物旗下的全资子公司,希麦迪是一家成立于2017年1月,主要从事药物临床试验服务的合同研究组织(CRO),能够提供包括注册申报、医学事务、临床运营、数据管理和生物统计、药物警戒,以及生物样本分析等业务在内的创新药及医疗器械的临床试验服务。

详情请访问公司网站:www.crmedicon.com

Pharmaron Acquires Majority Stake in CR Medicon

Expands Pharmaron’s integrated offerings to clinical development in China

Beijing, China, May 21, 2019 - Pharmaron, a fully integrated contract research organization offering R&D services for the life science industry, announced today that it has completed a follow-on investment in CR Medicon Holding Inc. (together with its wholly owned subsidiary, Nanjing CR Medicon Pharmaceutical Technology Co., Ltd. “CR Medicon”), a clinical CRO based in Nanjing, China. As such, Pharmaron holds majority ownership of CR Medicon after this transaction. This investment follows the path of Pharmaron’s previous strategic investments made in CR Medicon in 2018, reflecting its continued confidence in CR Medicon and strong commitment to clinical development service. It demonstrates Pharmaron’s global clinical development service strategy, together with its US-based Clinical Pharmacology Center (CPC), to create additional, synergistic value for domestic and international partners.

Dr. Boliang Lou, Chairman and CEO, Pharmaron, commented, “We are delighted to have CR Medicon join the Pharmaron family. This transaction will set up a new business line in China for Pharmaron and facilitate the full realization of Pharmaron’s global clinical development service strategy. The synergy is generated through close interaction among our clinical service offerings in China, US and UK and will help us better serve our partners. In addition, it accelerates our clinical development process and creates additional value for our partners, employees and stake-holders.”

Dr. Henry Wu, CEO, CR Medicon, commented, “CR Medicon has been striving to provide high quality clinical services to our partners. We are excited to become a member of Pharmaron Group as this will allow full integration with its global R&D platform to better serve the pharmaceutical R&D community.”

By combining both parties’ capabilities in clinical development services area, this transaction expands Pharmaron’s fully integrated drug discovery and development service platform. This arrangement further demonstrates the company’s commitment to becoming a global leader in the life science service industry. Pharmaron continues to uphold its original aspiration to support partners’ success in discovery, development and commercialization of innovative medicines.

About Pharmaron

Pharmaron is a public-owned, premier R&D service provider for the life sciences industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of R&D service capabilities ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism, clinical pharmacology, clinical analytical sciences to chemical & pharmaceutical development. With over 6,500 employees, and operations in China, the United States, and the United Kingdom, Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.

www.pharmaron.com

About MedIcon

CR MedIcon is a full-service clinical CRO that was established in 2017. Its current service areas include regulatory affairs, medical affairs, clinical operation, clinical data management and biostatistics, pharmacovigilance, and bioanalysis of clinical samples to support the needs from clinical trials for innovative drugs and devices. 

www.crmedicon.com

微信公众号